dronate-induced interstitial nephritis with subsequent Fanconi syndrome. We report here a case of interstitial nephritis-Fanconi syndrome associated with the administration of zoledronate.
Case Report
A 54-year-old female underwent mastectomy in 1992 for breast cancer. Resection surgery was also carried out in 2000 for lung metastasis. After surgery, she did not develop dehydration. Treatment with docetaxel commenced in 2004 for liver metastasis but was later discontinued due to nausea, and replaced with trastuzumab in 2005. Treatment with zoledronate (4 mg/month) combined with radiotherapy for occipital bone and left calcaneus commenced in the same year for bone metastasis. No other oral drugs were used except trastuzumab and zoledronate and progressive hypokalemia and renal dysfunction were observed from 2006. As dry mouth, poly-regular, and body temperature 36.5°C. The patient was fully alert and no abnormalities were evident on examination of the thorax and abdomen. There was no peripheral edema and the tendon reflexes were normal.
Laboratory blood and urine analyses on admission were shown (Tables 1, 2) . Laboratory tests showed renal dysfunction as evident by 24-hour endogenous dipsia, and polyuria were appeared and hypokalemia (plasma potassium: 2.2 mEq/L) as well as renal dysfunction (serum creatinine: 2.0 mg/dL) were observed, necessitating admission of the patient to our department for further management. At admission, height was 163 cm, body weight 52 kg (body mass index (BMI) 19.4 kg/m 2 ), blood pressure 94/62 mmHg, pulse rate 56 beats/minute, showed urinary phosphorus of 20.8 mg/dL, glucosuria (11.76 g/day), albuminuria (1.32 g/day), β2-microglobinuria (55,400 μg/L), and generalized aminoaciduria (Table 2) . Despite the glucosuria, fasting blood glucose was 95 mg/dL and HbA1c (estimated as the National Glycohemoglobin Standardization Program (NGSP)) was 6.1%, indicating that the cause of glucosuria was renal diabetes. With a normal anion gap metabolic acidosis and impaired ammonium excretion, hypokalemia, hypophosphatemia and glucosuria, the diagnosis of proximal renal tubular acidosis with Fanconi syndrome was considered.
A renal biopsy showed scattered formation of cylinders inside the proximal renal tubules, infiltration of inflammatory cells around the proximal tubules and stroma of the same region, and interstitial edema (Fig. 1) . The glomeruli were almost normal and staining was negative for immunoglobulin, complement, and fibrinogen. From these results, the patient was diagnosed with comcreatinine clearance of 24.5 mL/min, blood urea nitrogen 17 mg/dL, serum creatinine 1.97 mg/dL, estimated glomerular filtration rate (eGFR) 21.7 mL/min/1.73 m 2 . Blood electrolytes showed hypokalemia (potassium 2.5 mEq/L), hypocalcemia (calcium 8.0 mg/ dL), hypophosphatemia (phosphorus 1.8 mg/dL) and hypouricemia (uric acid 1.8 mg/dL). Arterial blood gas analysis showed pH 7.292, PaO 2 105 mmHg, PaCO 2 34.9 mmHg, HCO 3 -16.5 mEq/L and metabolic acidosis with a normal anion gap. The normal anion gap and normal gastrointestinal function suggested that the cause of metabolic acidosis was renal tubular acidosis. Moreover, fractional excretion of potassium was 61.0%, fractional excretion of uric acid was 83.3% (normal range, 6-20%), and tubular maximal transport of phosphate reabsorption to the glomerular filtration rate transport (TmP/GFR) was 0.4 (normal range, 2.3-4.3). Based on these findings, the diagnosis was considered hypokalemia with renal tubular acidosis. Other tests as precipitating factors [3] . However, it is thought that renal dysfunction improves slowly after discontinuation of bisphosphonates and is likely to occur following prolonged administration. In fact, one study reported the development of renal dysfunction (increase in serum creatinine of 0.5 mg/dL) in 9.3% (23/246) of patients administered 4 mg/15 minute of phase III zoledronate testing and that the frequency of renal dysfunction depended on the administration time and dosage [4] . Yoshinami et al. [5] reported recently a case of Fanconi syndrome caused by zoledronate, but they did not perform renal biopsy. To date, three reports have investigated zoledronate-induced renal dysfunction by renal biopsy in 8 patients [6] [7] [8] ; however, these patients included 6 with diffuse tubular necrosis, 1 with collapsing focal glomerulosclerosis, and 1 with acute tubular necrosis, but none with Fanconi syndrome associated with interstitial nephritis.
Bisphosphonates are mainly excreted by the kidneys and because their clearance is larger than GFR, bisphosphonates are also secreted by the renal tubules [9] . Therefore, it is assumed that bisphosphonates is toxic to the glomeruli, renal tubules and stroma. With regard to the mechanism of nephrotoxicity, bisphosphonates is considered to plete Fanconi syndrome induced by interstitial nephritis.
In this case, the cause of interstitial nephritis was most likely drug related, since it was adult-onset and she didn't have any allergies. Because she didn't have any other medications except zoledronate and trastuzumab, zoledronate was discontinued first. This resulted in immediate and sustained amelioration of β 2 -microglobulinuria, albuminuria, glucosuria over several months and normalization of these parameters at 12 months after discontinuation (Fig. 2) . Together with these changes, renal function improved with increase in eGFR to 39 mL/min/1.73 m 2 and significant improvement in aminoaciduria (data not shown).
Discussion
To our knowledge, this is the first report of Fanconi syndrome in a patient with zoledronate-induced interstitial nephritis. The reported incidence of acute tubular necrosis in patients treated with bisphosphonates is 2 to 10% [2] . Bisphosphonates are secreted from the renal tubules and accordingly considered to cause direct damage of tubular cells, with slowly progressive renal dysfunction. In particular, old age, and weight are listed Advancement of renal dysfunction following the commencement of zoledronate (4 mg/month). Proteinuria, β2-microglobulinuria, and glucosuria were observed at admission to our hospital. However, recovery was noted following discontinuation of zoledronate, including improvement of renal function.
ment in high-sensitivity TNF-α and IL-6 was observed following discontinuation of zoledronate (data not shown), suggesting a similar mechanism may have been involved. In this regard, Tokuyama et al. [15] reported serious cellular dysfunction following exposure of cultured VγVδ T cells to certain drugs such as rituximab and/or trastuzumab. Considered together, these results suggest that care must be exercised when bisphosphonate and trastuzumab are used together therapeutically. The use of the combination therapy of bisphosphonate and other drugs is expected to increase in the future in patients with breast cancer and bone metastases. In such cases, clinical manifestations of tubular injury may not appear over a long time. Therefore, caution should be exercised, especially to patients treated concomitantly with these molecular target drugs, including careful monitoring of renal function (serum creatinine, albuminuria, marker of proximal tubular injury) and long-term follow-up.
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induce apoptosis of epithelial cells in the glomeruli and/or proximal renal tubules through the mevalonate pathway, similar to its apoptotic effects on osteoclasts [10] .
Our patient developed advanced proximal tubular injury over a long period of 4 years following the combined use of trastuzumab and zoledronate for breast cancer. While we have no direct link between these two medications and the development of Fanconi syndrome, the case report provides circumstantial evidence: Fanconi syndrome developed after such treatment and recovery was observed following discontinuation of zoledronate. Infiltration of inflammatory cells into the renal tubules and the stroma of the proximal tubules were observed on histopathological examination of the renal biopsy, suggesting that Fanconi syndrome occurred following chronic interstitial nephritis. In this patient, renal dysfunction progressed during the course of several years following the administration of zoledronate, different from past reports. Moreover, no glomerular injury was observed in renal biopsies examined in previous reports, suggesting a likely different mechanism.
Previous studies have reported the side effects of the combination treatment of bisphosphonate and trastuzumab. Guarneri et al. [11] reported that the concomitant use of bisphosphonate and trastuzumab resulted in necrosis of the mandible in 3 of 9 patients, whereas treatment with bisphosphonate alone did not cause bone necrosis in any of the 19 patients with breast cancer and bone metastasis who received intravenous bisphosphonate. Based on the extremely low incidence of bisphosphonate toxicity (0.03 to 6.2%), these authors concluded that the combined use of bisphosphonate and trastuzumab resulted in necrosis of the mandible and cautioned against the use of this combination therapy.
In another report, intravenous administration of bisphosphonate was described to induce influenza-like "acute-phase reaction" [12] . However, recent studies indicated that this reaction was mediated by induction of TNF-α and IL-6 [13] , which accompanies the activation of VγVδ T cells [14] . In our patient, marked improve-
